4-Bromo-8,11,15-trioxa-17-azapentacyclo[8.7.0.01,14.02,7.010,14]heptadeca-2(7),3,5,16-tetraen-16-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噁庚英
• 英文名称: 4-Bromo-8,11,15-trioxa-17-azapentacyclo[8.7.0.01,14.02,7.010,14]heptadeca-2(7),3,5,16-tetraen-16-amine
• 英文别名: 4-bromo-8,11,15-trioxa-17-azapentacyclo[8.7.0.01,14.02,7.010,14]heptadeca-2(7),3,5,16-tetraen-16-amine
• 化学式: C₁₃H₁₁BrN₂O₃
• 分子量: 323.14
• InChiKey: JTWKEQDYJJNQOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  66.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• US9242973B2
  申请人：——

  公开号：US9242973B2

  公开（公告）日：2016-01-26
• [EN] CHROMANE COMPOUNDS<br/>[FR] COMPOSÉS DE CHROMANE
  申请人：ASTELLAS PHARMA INC

  公开号：WO2013181202A2

  公开（公告）日：2013-12-05

  The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing or treating diseases or conditions associated with and/or mediated by β-secretase activity, hydrolysis of a β-secretase site of a β -amyloid precursor protein, and/or β -amyloid protein accumulation, including a pharmaceutical composition for preventing or treating diseases including, but not limited to, Glaucoma, MCI (Mild cognitive impairment) or Alzheimer's disease, especially, Alzheimer's disease.